ACHV
Achieve Life Sciences, Inc. NASDAQ$4.39
Mkt Cap $233.7M
52w Low $2.00
59.3% of range
52w High $6.03
50d MA $3.94
200d MA $3.93
P/E (TTM)
-3.5x
EV/EBITDA
-3.9x
P/B
8.9x
Debt/Equity
0.7x
ROE
-254.0%
P/FCF
-4.4x
RSI (14)
—
ATR (14)
—
Beta
1.96
50d MA
$3.94
200d MA
$3.93
Avg Volume
972.5K
About
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agre…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.27 | -0.28 | -3.7% | 2.90 | +4.5% | -2.8% | -0.3% | -8.6% | -7.9% | +1.4% | — |
| Nov 6, 2025 | AMC | -0.24 | -0.28 | -16.7% | 4.74 | -1.5% | -3.2% | -6.1% | +0.6% | -0.4% | -3.4% | — |
| Aug 7, 2025 | AMC | -0.37 | -0.37 | +0.0% | 2.64 | -1.9% | -5.3% | -7.2% | -7.6% | -3.8% | -3.4% | — |
| May 13, 2025 | AMC | -0.37 | -0.37 | +0.0% | 2.65 | -0.4% | -6.4% | +3.0% | +16.2% | +24.9% | +23.0% | — |
| Mar 11, 2025 | AMC | -0.30 | -0.36 | -20.0% | 2.92 | +0.3% | -9.2% | -9.2% | -5.5% | -0.3% | -4.8% | — |
| Nov 7, 2024 | AMC | -0.26 | -0.36 | -38.5% | 5.00 | -5.4% | -7.4% | -10.6% | -7.0% | -9.4% | -12.2% | — |
| Aug 13, 2024 | AMC | -0.22 | -0.25 | -13.6% | 4.36 | -1.4% | +0.5% | +2.1% | +3.2% | +6.2% | +1.1% | — |
| May 9, 2024 | AMC | -0.24 | -0.26 | -8.3% | 4.53 | +2.6% | +1.8% | +6.2% | +10.6% | +15.0% | +11.9% | — |
| Mar 28, 2024 | AMC | -0.32 | -0.26 | +18.8% | 4.55 | +2.0% | +0.7% | -1.5% | +0.9% | -1.5% | -2.0% | — |
| Nov 9, 2023 | AMC | -0.34 | -0.34 | +0.0% | 4.19 | +0.6% | -1.9% | +0.2% | +7.4% | +16.0% | +22.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | Canaccord Genuity | Initiates | Buy | $13 | $4.25 | $4.37 | +2.8% | -0.9% | -0.5% | -2.4% | -5.4% | -6.8% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.55 | $4.05 | +14.1% | +35.5% | +43.7% | +19.7% | +18.6% | +19.2% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.90 | $3.03 | +4.5% | -2.8% | -0.3% | -8.6% | -7.9% | +1.4% |
| Aug 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.38 | $4.49 | +2.5% | +1.6% | +2.7% | +5.7% | +0.7% | +1.4% |
| May 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.61 | $4.68 | +1.5% | +4.3% | +8.7% | +13.0% | +10.0% | +8.5% |
| Apr 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.55 | $4.64 | +2.0% | +0.7% | -1.5% | +0.9% | -1.5% | -2.0% |
| Mar 5 | Lake Street | Maintains | Buy → Buy | — | $4.42 | $4.40 | -0.5% | -0.7% | +0.2% | -0.9% | -0.7% | -1.6% |
| Dec 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.45 | $3.89 | -28.6% | -42.2% | -39.1% | -39.8% | -41.7% | -39.3% |
| May 31 | Lake Street | Maintains | Buy → Buy | — | $6.24 | $6.21 | -0.5% | -0.6% | +3.5% | +8.0% | +3.4% | +0.6% |
| May 10 | Lake Street | Maintains | Buy → Buy | — | $8.81 | $8.97 | +1.8% | +12.7% | +0.8% | -6.7% | -11.0% | -10.3% |
Recent Filings
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CEO Richard Stewart's departure amid a private placement signals potential leadership instability and dilution concerns, warranting investor scrutiny on succession clarity and capital allocation rationale.
Apr 16
8-K
Unknown — 8-K Filing
Achieve's CEO signals confidence in cytisinicline's commercial potential as a first-in-class smoking cessation drug, positioning it as a transformative treatment that could significantly expand the addressable market if approved.
Mar 24
Data updated apr 24, 2026 10:32am
· Source: massive.com